2010 Top 20 Pharmaceutical Companies Report

By Gil Roth | July 9, 2010

Slowing sales, mega-mergers, generic implosions and whipsawing exchange rates have caused some shakeups within the Top 20 Pharma ranks. The loss of Wyeth and Schering-Plough, coupled with Roche’s defection to the Biopharma list, led us to find several new players: Otsuka, Gilead and Mylan.

I’m not sure how significant it is that half of “the second tier” (companies 11-20) are based in Japan, but I find it interesting that Gilead (#19) is the only non-generic U.S. pharma company in that tier. (Just below the cutoff line, companies #21 and #22 are Dutch and Japanese, respectively.) I also find it interesting that Teva has revenue goals that could propel it into the top 7 ranks in the next few years. Aim high, pharma!

Gil Y. Roth, Editor


Top 20 Pharmaceutical Companies
01 Pfizer $45,448
02 Sanofi-Aventis $40,871
03 Novartis $38,455
04 GlaxoSmithKline $36,746
05 AstraZeneca $31,905
06 Merck & Co. $26,929
07 Johnson & Johnson $22,520
08 Eli Lilly & Co. $20,629
09 Bristol-Myers Squibb $18,808
10 Abbott Laboratories $16,486
11 Takeda Chem. Ind. $14,204
12 Boehringer-Ingelheim $14,027
13 Teva Pharma $13,814
14 Bayer Schering $13,344
15 Astellas $10,509
16 Daiichi-Sankyo $9,757
17 Eisai $8,441
18 Otsuka $7,717
19 Gilead Sciences $6,469
20 Mylan $5,015

Based on 2009 pharma revenues.
Note: In all Top Company profiles, dollar amounts are in millions.



Editor: Gil Y. Roth
Associate Editor: Kristin Brooks
Contributing Editor: Derek B. Lowe

All profiles written by Gil Roth, except Astellas and Daiichi-Sankyo, by Kristin Brooks.

The Lowe Down capsules written by Derek Lowe

All pipeline information compiled by Kristin Brooks

Sales information compiled by Gil Roth

Visit our Top 10 Biopharma companies report!


Back to the July/August 2010 issue

Related Packaging:

  • Packaging Equipment Technology Preview

    Packaging Equipment Technology Preview

    February 15, 2017
    Today’s complex drug products present challenges; the latest equipment capabilities help overcome them

  • The Good, the Bad, and the Donald

    The Good, the Bad, and the Donald

    January 31, 2017
    Orphan drugs, CMO continuous manufacturing and developing world sales offer biggest revenue opportunities

  • Predictive Analytics and the Future of RBM

    Rajneesh Patil, Senior Director, RBM and Analytics, QuintilesIMS||January 23, 2017
    How advances in Risk-Based Monitoring will enable a more proactive approach to identify and mitigate potential risks